AmpliMed Corporation   Report issue

For profit Phase 2
Founded: Tuscon Arizona United States (1989)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2004
NCT00327327
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4